Items tagged with Research and development
TB community reiterates request to Johns Hopkins to review sutezolid licensing agreement with Sequella (post with simple image)
The TB CAB and TAG restate their request to Johns Hopkins University to allow representatives of TB-affected communities to comment on the terms of any agreement with Sequella before it is finalized.
Tuberculosis R&D “grossly insufficient” according to new report (post with simple image)
With just $255 million spent on TB research and development each year, funding is currently just one-third of the annual target set by the Global Plan to Stop TB 2011-2015.
ACTION ALERT: Urge Johns Hopkins University to accelerate important TB innovation & keep it accessible for all (post with simple image)
Take Action for TB Today! Sign and share this petition now: https://uaem.wufoo.com/forms/z1dxtbgq0ieib3a/
Appeal to develop VXc-486 for tuberculosis (post with simple image)
Advocates urge Vertex to assure the timely and responsible development of drug candidate VXc-486 for tuberculosis.
The FDA’s concession conundrum (post with simple image)
Can regulatory incentives promote responsible TB drug development?
The 21st Century Cures Act’s “pathway to crisis” in drug safety (post with simple image)
Federal legislation promises a substantial increase in NIH funding — at the expense of a significantly weakened FDA.
Tuberculosis research funding crisis imperils elimination goal (post with simple image)
TAG's annual Report on Tuberculosis Research Funding Trends shows that worldwide funding for tuberculosis research fell $1.3 billion short of global targets in 2014.
Global pharmaceutical industry calls on governments to work with them to beat the rising threat of antimicrobial resistance (post with simple image)
In a joint declaration more than 80 leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, call on governments and industry to work in parallel in taking comprehensive action against antimicrobial resistance.
UNITAID study looks at delinking cost of R&D from price of medicines (post with simple image)
The study explores how to separate the costs of research and development (R&D) from the future market price of vaccines, medicines and diagnostics – a concept known as “delinkage”.
UAEM calls for a people-centered approach to biomedical R&D (post with simple image)
Universities Allied for Essential Medicines (UAEM) launches Re:Route, a mapping of alternative biomedical research and development (R&D) initiatives.
Page 12 of 15 · Total posts: 0←First 11 12 13 Last→